Knockdown of a Proliferation-inducing Ligand (PRIL) Suppresses the Proliferation of Gastric Cancer Cells

  • Cui, Jiu-Wei (Cancer Center of the First Hospital of Jilin University) ;
  • Li, Yan (School of Life Science & Technology, Beijing Institute of Technology) ;
  • Wang, Chang (Cancer Center of the First Hospital of Jilin University) ;
  • Yao, Cheng (Cancer Center of the First Hospital of Jilin University) ;
  • Li, Wei (Cancer Center of the First Hospital of Jilin University)
  • Published : 2012.02.29


Purpose: PRIL (proliferation-inducing ligand) is a newly identified member of the tumor necrosis factor (TNF) family and modulates death ligand-induced apoptosis. Here, we investigated the effect of PRIL on cellular characteristics relating to tumor progression in human gastric cancer. Method: Recombinant lentivirus containing PRIL siRNA was constructed and then infected MGC803 and SGC7901 gastric cancer cells. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colony formation and cell cycle analysis were used to study the effect of PRIL knockdown on gastric cancer cell proliferation. Results: PRIL expression in lentivirus infected cells was significantly reduced as evidenced by quantitative real-time PCR. Cell viability and colony formation of MGC803 and SGC7901 cells were significantly hampered in PRIL knock-down cells. Moreover, the cell cycle was arrested at G2/M phase, elucidating the mechanism underlying the inhibitory effect of siRNA on cell proliferation. Conclusions: Our study indicated that PRIL functions in promoting cell growth, and lentivirus-mediated PRIL gene knockdown might be a promising strategy in the treatment of gastric cancer.


APRIL;lentivirus;gastric cancer;proliferation


  1. Batten M, Fletcher C, Ng LG, et al (2004). TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol, 172, 812-22.
  2. Chiu A, Xu W, He B, et al (2007). Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood, 109, 729-39.
  3. Chu VT, Enghard P, Riemekasten G, et al (2007). In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol, 179, 5947-57.
  4. Deshayes F, Lapree G, Portier A, et al (2004). Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene, 23, 3005-12.
  5. Fire A, Xu S, Montgomery MK, et al (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-11.
  6. Fish RJ, Kruithof EK (2004). Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol, 5, 9.
  7. Hahne M, Kataoka T, Schroter M, et al (1998). APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med, 188, 1185-90.
  8. He B, Chadburn A, Jou E, et al (2004). Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol, 172, 3268-79.
  9. Ingold K, Zumsteg A, Tardivel A, et al (2005). Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med, 201, 1375-83.
  10. Kalled SL, Ambrose C, Hsu YM (2005). The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun, 8, 206-42.
  11. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.
  12. Kelly K, Manos E, Jensen G, et al (2000). APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res, 60, 1021-7.
  13. Kern C, Cornuel JF, Billard C, et al (2004). Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood, 103, 679-88.
  14. Li W, Li Y, Tan Y, et al (2010) Bmi-1 is critical for the proliferation and invasiveness of gastric carcinoma cells. J Gastroenterol Hepatol, 25, 568-75.
  15. Li W, Yu CP, Xia JT, et al (2009). Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res, 15, 1393-9.
  16. Lopez-Fraga M, Fernandez R, Albar JP, et al (2001). Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep, 2, 945-51.
  17. Marsters SA, Yan M, Pitti RM, et al (2000). Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol, 10, 785-8.
  18. Moreaux J, Legouffe E, Jourdan E, et al (2004). BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 103, 3148-57.
  19. Naldini L, Blomer U, Gallay P, et al (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272, 263-7.
  20. Nardelli B, Belvedere O, Roschke V, et al (2001). Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood, 97, 198-204.
  21. Pelekanou V, Kampa M, Kafousi M, et al (2008). Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer, 8, 76.
  22. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al (2004). APRIL promotes B-1 cell-associated neoplasm. Cancer Cell, 6, 399-408.
  23. Rennert P, Schneider P, Cachero TG, et al (2000). A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med, 192, 1677-84.
  24. Resende C, Ristimaki A, Machado JC (2010). Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter, 15, 34-9.
  25. Roth W, Wagenknecht B, Klumpp A, et al (2001). APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ, 8, 403-10.
  26. Stein JV, Lopez-Fraga M, Elustondo FA, et al (2002). APRIL modulates B and T cell immunity. J Clin Invest, 109, 1587- 98.
  27. Wang H, Tan SS, Wang XY, et al (2007). Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells. Acta Pharmacol Sin, 28, 1968-74.
  28. Yaccoby S, Pennisi A, Li X, et al (2008). Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia, 22, 406-13.
  29. Yu GZ, Chen Y, Wang JJ (2009). Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol, 135, 1331-9.

Cited by

  1. ER81-shRNA Inhibits Growth of Triple-negative Human Breast Cancer Cell Line MDA-MB-231 In Vivo and in Vitro vol.13, pp.5, 2012,
  2. RNA Interference: a Promising Therapy for Gastric Cancer vol.15, pp.14, 2014,
  3. Silibinin Inhibits Proliferation, Induces Apoptosis and Causes Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells Via STAT3 Pathway Inhibition vol.15, pp.16, 2014,
  4. Identification of the sAPRIL Binding Peptide and Its Growth Inhibition Effects in the Colorectal Cancer Cells vol.10, pp.3, 2015,
  5. Tumor necrosis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryngeal squamous cell carcinoma vol.37, pp.2, 2016,